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Abstract
Background
Postnatal corticosteroids (PNC) were widely used to treat and prevent bronchopulmonary
dysplasia in preterm infants until studies showed increased risk of cerebral palsy and neuro-
developmental impairment. We aimed to describe PNC use in Europe and evaluate the
determinants of their use, including neonatal characteristics and adherence to evidence-
based practices in neonatal intensive care units (NICUs).
Methods
3917/4096 (95,6%) infants born between 24 and 29 weeks gestational age in 19 regions of
11 European countries of the EPICE cohort we included. We examined neonatal character-
istics associated with PNC use. The cohort was divided by tertiles of probability of PNC use
determined by logistic regression analysis. We also evaluated the impact of the neonatal
unit’s reported adherence to European recommendations for respiratory management and
a stated policy of reduced PNC use.
Results
PNC were prescribed for 545/3917 (13.9%) infants (regional range 3.1–49.4%) and for
29.7% of infants in the highest risk tertile (regional range 5.4–72.4%). After adjustment,
independent predictors of PNC use were a low gestational age, small for gestational age,
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male sex, mechanical ventilation, use of non-steroidal anti-inflammatory drugs to treat per-
sistent ductus arteriosus and region. A stated NICU policy reduced PNC use (odds ratio
0.29 [95% CI 0.17; 0.50]).
Conclusion
PNC are frequently used in Europe, but with wide regional variation that was unexplained by
neonatal characteristics. Even for infants at highest risk for PNC use, some regions only
rarely prescribed PNC. A stated policy of reduced PNC use was associated with observed
practice and is recommended.
Introduction
Bronchopulmonary dysplasia (BPD) is a chronic lung disease frequently associated with very
preterm birth [1,2] and defined as the need for oxygen at 36 weeks gestational age (GA) [3].
Inflammatory mechanisms in BPD have been described [4]. Therefore, postnatal corticoste-
roids (PNC) have been used to wean infants off ventilators [5]. In the 1990s, up to 25% of very
preterm infants received dexamethasone [6].
Dexamethasone has been found to be effective for decreasing BPD, BPD or mortality, as a
composite outcome, and facilitating extubation, but adverse effects include hyperglycemia, hyper-
tension, gastrointestinal bleeding or perforation, and hypertrophic cardiomyopathy. Longer term
consequences include a higher risk of cerebral palsy. [7–11]. The evidence for the use of other
PNC is weak. There have been only a few trials of hydrocortisone to prevent BPD [12]. Only one
study showed a reduction of BPD, but long term outcome wasn’t assessed [13]. Results from an
observational study showing reduced white matter injury with betamethasone compared to dexa-
methasone in antenatal care [14] led to a preference for betamethasone as postnatal steroid ther-
apy for BPD, but no trial results have been published for this indication. In 2002, the American
Academy of Pediatrics and Canadian Paediatric Society published recommendations concerning
PNC [15], revised in 2012 [16]: the routine use of PNC to prevent or treat BPD should be
avoided; because of adverse effects, its use should be limited to exceptional clinical circumstances
after parental information and PNC initiation should be delayed at least after 7 days of life.
After the publication of the AAP-recommendations, the use of PNC decreased [6,17,18].
However, the Models for OrganiSing Access to Intensive Care For Very Preterm Babies in
Europe (MOSAIC) study showed that PNC was still in use in Europe in 2003, with rates from
4% to 35% among regions [19].
The Effective Perinatal Intensive Care in Europe (EPICE) study enrolled a population-based
cohort of births before 32 weeks GA that occurred in 2011 and 2012 in 19 regions in 11 European
countries. The study aimed to assess the use of evidence-based medicine for the care of very pre-
term infants. In this paper, we describe the rate of PNC use in participating EPICE regions and
identify determinants of its use, including case-mix characteristics and neonatal intensive care
unit (NICU) policies. Our hypothesis is that evidence-based policies can reduce PNC use.
Methods
Study design
The EPICE cohort is a geographically defined study of all very preterm stillbirths and live births
from 22 +0 to 31 +6 weeks GA in 19 European regions. Data collection started between March
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and July 2011 and the inclusion period lasted 12 months, except in France, where it lasted 6
months.
Study population
For this study, all infants admitted to a neonatal unit were included. We excluded infants born
before 24 weeks GA because of heterogeneous management of this subgroup in participating
regions and infants born after 29+6 weeks GA because of reduced risk of BPD [20]. The flow
chart is displayed in Fig 1.
Fig 1. Flow chart of infants who met inclusion/exclusion criteria for the study. PNC, postnatal corticosteroids; NICU,
neonatal intensive care unit; GA: gestational age.
doi:10.1371/journal.pone.0170234.g001
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Data collection
Data on infants were collected using a standardised and pretested questionnaire from obstetri-
cal and neonatal medical records. Data on the characteristics and practices of NICUs provid-
ing care for very preterm infants in participating regions were collected by use of a structured
questionnaire sent to NICU administrative heads by mail or e-mail. Questions were formu-
lated so that they could be answered in the same way by different staff members and several
people within the NICU could discuss responses and complete the questionnaire. Data were
collected on the structural characteristics of NICUs (level of specialization), their activity levels
in 2011, policies, protocols and practices related to selected medical interventions, ethical deci-
sions, decision-making processes and existence of healthcare quality monitoring systems.
NICUs with at least 10 very preterm admissions per year and their associated maternity
units were included in the unit studies. These parameters were fixed before the study’s onset.
Ethics approval was obtained in each study region from regional and/or hospital ethics
committees, as required by national legislation. The European study was also approved by the
French Advisory Committee on Use of Health Data in Medical Research and the French
National Commission for Data Protection and Liberties.
Study outcome
The outcome in this study was the specific use of systemic PNC to treat BPD, including the
type of steroid used, the initial dose, the age at initiation, and the length of treatment. When
systemic steroids for this indication were given before 36 weeks GA, we considered they were
used for infants with respiratory disease at high risk of BPD.
Neonatal characteristics
GA was based on ultrasound measures and information on last menstrual period. Small for
gestational age (SGA) was defined by a birthweight <10th percentile by using references gener-
ated from all live births in the EPICE cohort. We distinguished babies with a birthweight
between the 10th and 25th percentile as they have been found to be at higher risk of mortality
and respiratory morbidity [21]. Birthweight, sex, type of pregnancy (singleton or multiple),
mode of delivery, Apgar score at 5 min of life, surfactant therapy, mechanical ventilation, and
use of non-steroidal anti-inflammatory drugs (NSAIDs) to treat persistent ductus arteriosus
(PDA) were recorded. Antenatal steroids were scored as used if at least one dose had been
given. Preterm premature rupture of membranes (PROM) was defined as a rupture of the
membranes lasting longer than 12 hours before labor onset. Preeclampsia or eclampsia or
Hemolysis, Elevated Liver enzyme Low Platelet (HELLP) syndrome was summarized as one
variable.
NICU policies on evidence-based practices
Using questions from the NICU questionnaire, we generated 2 variables to reflect each unit’s
adherence to evidence-based practices. The first definition was based on the 2010 European
guidelines for managing respiratory distress syndrome in very preterm infants [22]. We classi-
fied the NICU as having an evidence-based approach if the NICU reported that they adminis-
tered surfactant to all newborns born before 26 weeks GA and to all newborns requiring
intubation in the delivery room, as recommended. The second definition relied on declared
policies concerning PNC prescription. We considered the NICU as having an evidence-based
approach if it reported a “PNC restricted use policy”. The NICU was classified as evidence-
based if it answered “no (or exceptional circumstances)” to both questions “In the unit, are
Postnatal Corticosteroid-Use in Europe: Practices and Determinants, a Cohort Study
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systemic postnatal corticosteroids given to infants less than 32 weeks GA to prevent BPD” or
“to treat BPD”. We analysed the effect of both approaches on PNC use separately.
Statistical analysis
We used descriptive statistics to portray PNC prescription by region. We analysed the associa-
tion between perinatal characteristics and PNC prescription by Student t or Mann-Whitney U
test for quantitative variables and chi-square or Fisher exact test for qualitative variables. Vari-
ables with p< 0.2 on univariate analysis were included in a stepwise logistic regression analy-
sis. The selected variables were consistent with the literature as risk factors for BPD [1,2]. For
each infant, we then estimated the probability of receiving PNC by the logistic regression
model, stratifying the sample by tertiles of probability of receiving PNC, as a risk profile, and
selected the infants in the highest tertile (highest risk profile) for analysing PNC prescription.
This subgroup included infants with the most severe respiratory condition. Finally, we ana-
lyzed the association between reported NICU policy for evidence-based practices and PNC
prescription with a two-level hierarchical linear mixed model, with patients as the first level
and the NICU as the second level. This last analysis involved the whole population and infants
in the highest probability tertile. Results are expressed as crude and adjusted odd ratios (ORs)
with 95% confidence intervals (95% CIs). All analyses were done using SAS 9.3 (SAS Inst. Inc.,
Cary, NC, USA).
Results
Use of PNC and variation across regions
Among newborns fulfilling inclusion criteria, 179/4096, or 4.3% had missing data on PNC pre-
scription. The characteristics of the final sample retained for the analysis (3917 newborns) are
described in Table 1. Infants with missing data had lower gestational ages (mean: 26.7 versus
27.1) and more often SGA (19% versus 9%) (p<0.05) (data not shown).
In total, 545/3917 (13,9%) infants between 24 and 29 weeks GA received systemic PNC to
treat BPD (Fig 1). Rates varied significantly among regions, from 3.1% (5/162 in northern Por-
tugal) to 49.4% (39/79 in Saarland, Germany) (p<0.001) (Fig 2A). Dexamethasone, hydrocor-
tisone and betamethasone were used in 195/545 (35,8%), 184/545 (33,8%) and 76/545(13,9%)
of cases, respectively, and treatment was mixed for 59/545 (10,8%) of newborns (Table 2).
Twenty six percent of infants (N = 50/195) received dexamethasone within the first 2 weeks of
life. Twenty eight percent of infants received dexamethasone for more than 20 days (40 of 143
infants receiving dexamethasone, with data on treatment duration available). The type of drug
used within regions varied significantly (p<0.001) (Fig 3).
Neonatal determinants of PNC use
Low GA, SGA, male sex, mechanical ventilation and NSAIDs to treat PDA were significantly
associated with PNC use after multivariate analysis (Table 3). Apgar score < 7 and surfactant
treatment were no longer significant after adjustment.
Regional variation after case-mix adjustment
We used the five neonatal factors significantly associated with PNC use to calculate the proba-
bility of each infant receiving PNC. This probability could not be calculated for 28 infants
because of missing data. We carried out subgroup analysis on infants with the most severe dis-
ease, defined as the tertile with highest probability of receiving PNC. The predicted probability
of receiving PNC ranged from 17% to 66% in this group. In this subgroup, 392/1320 (29,7%)
Postnatal Corticosteroid-Use in Europe: Practices and Determinants, a Cohort Study
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of infants received PNC to treat BPD and this varied significantly among regions, from 5.4%
(2/37 infants) in Stockholm, Sweden to 72.4% (21/29 infants) in Saarland, Germany (p<0.001)
(Fig 2B).
A total of 266 NICUs were located in the study regions in 2011, and 135 fulfilled the inclu-
sion criteria. Of these, 134/135 (99,2%) provided completed questionnaires. In our sample, 69/
3917 (1.8%) infants were excluded from this analyses because they were hospitalized in neona-
tal units that did not fulfill the inclusion criteria or did not complete the questionnaire. Twelve
percent of neonatal units reported adherence to the European Association of Perinatal Medi-
cine guidelines about surfactant use. Thirty six percent reported a PNC restricted use policy.
We found no association between reported adherence to the European Association of Perina-
tal Medicine guidelines (21) and PNC use; however, infants hospitalized in units that declared
having a policy concerning PNC restricted use were significantly less likely to receive PNC
(Table 4).
Discussion
Our study showed that PNC are still used in Europe, with wide variations across regions. The
main neonatal characteristics associated with PNC use were low GA, SGA, male sex, receiving
mechanical ventilation, and PDA treatment with NSAIDs. However, these characteristics did
Table 1. Perinatal population characteristics.
Characteristics Infants 24–29 weeks’ GA admitted to an NICU
n = 3917
Gestational age (weeks). mean (SD) 27.1 (1.6)
Birth weight (g). mean (SD) 1105 (278)
Gestational age
24–25 weeks 748 (19.1)
26–27 weeks 1276 (32.6)
28–29 weeks 1896 (48.4)
Male gender 2139 (54.6)
Multiples 1173 (29.9)
Birth weight percentile
SGA <10th 363 (9.3)
10-25th 614 (15.7)
>25th 2940 (75.1)
Preeclampsia/eclampsia/HELLP 558/3871 (14.4)
PROM 981/3859 (25.4)
Caesarean section 2551/3892 (65.5)
Inborn 3456/3911 (88.4)
Apgar <7 at 5 min 837/3644 (23.0)
Antenatal steroids 3465/3884 (89.2)
Surfactant 2983/3910 (76.3)
Mechanical ventilation 3030/3907 (77.6)
NSAIDs to treat PDA 1110/3899 (28.5)
PNC 545 (13.9)
Data are no. (%) unless indicated and for 3917 infants unless indicated.
GA, gestational age; HELLP: Hemolysis Elevated Liver enzyme Low Platelet NICU, neonatal intensive care
unit; PNC, postnatal steroids; SGA, small for gestational age; PROM, premature rupture of membrane;
NSAIDs, non-steroidal anti-inflammatory drugs; PDA, persistant ductus arteriosus
doi:10.1371/journal.pone.0170234.t001
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not explain the wide variation in PNC prescription between regions, which persisted for
infants with the most severe respiratory condition (highest risk tertile). NICUs with a PNC
restricted use policy showed significantly lower PNC use.
For a quarter of infants who received dexamethasone, treatment was initiated in the first 2
weeks of life, and for another quarter it lasted for more than 20 days. Based on meta-analysis
results and the latest recommendations, this use could be considered inappropriate [23,24].
Both hydrocortisone and betamethasone were commonly used to treat BPD and this could
also be considered inappropriate as there was no evidence from trials at the time of the EPICE
study suggesting that either is effective for BPD reduction. Since then one randomised con-
trolled trial showed that hydrocortisone was effective for reducing BPD [13]. However there
was no long term assessment.
Infants with severe respiratory conditions, dependant on mechanical ventilation after the
first week of life, may benefit from PNC concerning BPD. However, our analyses by risk ter-
tiles found that some low risk infants received PNC. Moreover, for infants in the highest-risk
tertile, those with the most severe disease, some regions had low rates of PNC use showing that
the variability in PNC use could not be explained solely by neonatal case mix and also that
some regions used alternative strategies for managing severe respiratory complications.
We then considered evidence-based practices as a potential determinant of PNC use. Evi-
dence-based medicine is the judicious use of current best evidence for making decisions about
the care of individual patients [25]. The best evidence is from randomised controlled trials and
meta-analyses. However, there is no clear indicator to measure use of evidence-based practices
in neonatal medicine. We therefore developed two indicators. The first used the 2010 Euro-
pean Association of Perinatal Medicine (EAPM) guidelines [22] which relied on evidence pub-
lished up to 2009 and which was released before EPICE, conducted in 2011/2012. In 2010,
further studies showed less intubation and shorter mechanical ventilation for infants who
received early continuous positive airway pressure [26,27]. Therefore, systematic surfactant
became irrelevant, and was no longer recommended in the 2013 EAPM guidelines [24]. In
2011, as infants were included in the EPICE cohort, effective respiratory management evidence
was changing. The second indicator was a stated policy of restricted PNC use. Evidence of
PNC side effects is strong [8,28] and we considered a reported policy of restricted PNC use as
an evidence-based practice [8,15,29]. Our definition selects NICUs with a real will to restrict
PNC to exceptional circumstances. According to the current recommandations, dexametha-
sone should be restricted to infants under mechanical ventilation [9,30].
Our result that a lower probability of receiving PNC after consideration of case-mix was
related to the existence of a unit policy of restricted use of PNC is consistent with Kaemps
Fig 2. a) Rate of Postnatal Corticosteroid (PNC) use by region. b) Rate of PNC use by region for infants in the
highest risk tertile. PT: Portugal, PL: Poland, UK: United Kingdom, SE: Sweden, DK: Denmark, FR: France,
IDF: Ile de France, DE: Germany, IT: Italy, NL: The Netherlands, BE: Belgium,
doi:10.1371/journal.pone.0170234.g002
Table 2. PNC use for infants at 24–29 GA (N = 545).
Dexamethasone (35,8%) Hydrocortisone (33,8%) Betamethasone (13,9%)
Age at initiation (d) 24 (15–37) 12 (6–20) 21 (15–29)
Initial dose (mg/kg/d) 0.2 (0.15–0.5) 4.0 (1.7–5) 0.2 (0.1–0.3)
Treatment duration (d) 10 (6–20) 21 (11–29) 7 (4–12)
GA at birth (weeks) mean (sd) 25.6 (1.4) 26.0 (1.6) 26.5 (1.6)
Data are median (Q1-Q3) unless indicated.
doi:10.1371/journal.pone.0170234.t002
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et al., an interventional study that showed that implementing local recommendations for respi-
ratory management practices reduced dexamethasone use to treat BPD [31]. Our findings
show an impact of explicit policies on real clinical practice [32] and support the development
of clear unit policies for the use of evidence-based interventions or treatments.
While an explicit restricted use policy was a significant determinant of clinical practice,
questions remain about the large practice variations observed in our study. This could reflect
different interpretations of the evidence, in particular for infants at highest risk of BPD.
Doyle et al updated meta regression reported that in units with high rates of BPD, some
children under assisted ventilation might have an increased chance of survival without CP
[33]. However these results require confirmation at the individual level which would be possi-
ble in a randomized trial of infants at high predicted risk of BPD, as suggested by the authors.
The strengths of our study include its prospective population-based cohort design with few
missing data. Data for the type of steroids, initiation date and dose and length of treatment
were available. One limitation of our study is that our approach of evidence-based practices
relied on a questionnaire and not on individual data. However, the declared PNC restricted
use policy was associated with significantly reduced PNC use. Furthermore, despite a low miss-
ing data rate, newborns with missing data on PNC use were more immature and had lower
birthweight than infants without missing data, which could have implied a selection bias and
underestimated the PNC prescription rates. The next step will be to assess if low PNC use is
associated with different mortality or survival without BPD rates among EPICE NICUs.
Fig 3. Type of corticosteroids used to treat bronchopulmonary dysplasia (BPD), by region. PT: Portugal, PL: Poland, UK:
United Kingdom, SE: Sweden, DK: Denmark, FR: France, IDF: Ile de France, DE: Germany, IT: Italy, NL: The Netherlands, BE:
Belgium,
doi:10.1371/journal.pone.0170234.g003
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Table 3. Use of PNC by neonatal characteristics.
PNC P value crude Adj
n/N % OR 95% CI OR* 95% CI
GA
24–25 242/748 32.4 <0.0001 8.7 6.7–11.2 5.6 4.1–7.5
26–27 204/1276 16.0 <0.0001 3.4 2.7–4.4 2.5 1.9–3.3
28–29 99/1893 5.2 - - - -
Birthweight percentile
<10th 79/363 21.8 2.0 1.5–2.6 2.1 1.5–3.0
10-25th 110/614 17.9 1.6 1.3–2.0 1.4 1.1–1.9
>25th 356/2940 12.1 <0.0001 - - - -
Sex
Female 210/1778 11.8 0.001 - - - -
Male 335/2139 15.7 1.4 1.2–1.7 1.4 1.1–1.8
Multiple pregnancy
Singleton 392/2744 14.3 0.30 - - - -
Multiple 153/1173 13.0 0.9 0.7–1.1 0.9 0.7–1.2
PROM
No 413/2878 14.4 0.11 - - - -
Yes 121/981 12.3 0.8 0.7–1.0 0.9 0.7–1.1
Preeclampsia/eclampsia/HELLP
No 448/3313 13.5 0.16 - - - -
Yes 88/558 15.8 1.2 0.9–1.5 1.1 0.8–1.6
Caesarean
No 208/1341 15.5 0.03 - - - -
Yes 332/2551 13.0 0.8 0.7–1.0 1.1 0.9–1.4
Inborn
No 68/455 14.9 1.10 0.8–1.4 0.7 0.5–1.0
Yes 476/3456 13.8 0.5 - - -
Apgar score <7
No 343/2807 12.2 <0.0001 - - - -
Yes 150/837 17.9 1.6 1.3–1.9 0.9 0.7–1.2
Treatments
Antenatal steroids
No 62/419 14.8 0.62 - - - -
Yes 482/3465 13.9 0.9 0.70–1.2 1.1 0.8–1.5
Surfactant
No 36/927 3.9 <0.0001 - - - -
Yes 509/2983 17.1 5.1 3.6–7.2 1.3 0.8–1.9
Mechanical ventilation
No 10/877 1.1 <0.0001 - - - -
Yes 534/3030 17.6 18.5 9.9–34.8 7.7 3.8–15.8
NSAIDs to treat PDA
No 273/2789 9.8 <0.0001 - - - -
Yes 271/1110 24.4 3.0 2.5–3.6 1.8 1.5–2.3
* adjusted on gestational age
SGA, sex, PROM, preeclampsia/eclampsia/HELLP:, caesarean section, apgar score, surfactant, mechanical ventilation, NSAIDs to treat PDA
OR: odds ratio; 95% CI: 95% confidence interval. n: number receiving PNC N: total in group
doi:10.1371/journal.pone.0170234.t003
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Conclusion
European practices in PNC use for BPD are heterogeneous. Neonatal factors associated with
PNC prescription reflected in part disease severity but did not explain the variation in PNC
use. Our results suggest that a stated policy of restrictive PNC use could reduce non-evidence–
based practices for individual patients. Other potential determinants such as knowledge con-
cerning adverse effects, use of preventive respiratory strategies and saturation targets should
be considered.
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Table 4. Association of NICU practices and PNC use.
Practice No. of
NICUs
No. Of
infants
Infants at 24–29 weeks’
GA
Infants in the highest risk
tertile
n/N % n/N % Adj OR* 95% CI P value Adj OR* 95% CI P value
European Association of Perinatal Medicine
recommendations
16/132 12 369/3719 10 0.91 0.4–
2.1
0.83 0.82 0.3–2 0.65
NICU PNC restricted use policy 47/132 36 1069/3706 29 0.29 0.2–
0.5
<0.001 0.29 0.2–
0.5
<0.001
* adjusted on gestational age
SGA, sex, mechanical ventilation, NSAIDs to treat PDA
OR: odds ratio; 95% CI: 95% confidence interval. n: number using NICU Policy N: total in group
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